GB0906579D0 - Pharmaceuticals, compositions and methods of making and using the same - Google Patents

Pharmaceuticals, compositions and methods of making and using the same

Info

Publication number
GB0906579D0
GB0906579D0 GBGB0906579.8A GB0906579A GB0906579D0 GB 0906579 D0 GB0906579 D0 GB 0906579D0 GB 0906579 A GB0906579 A GB 0906579A GB 0906579 D0 GB0906579 D0 GB 0906579D0
Authority
GB
United Kingdom
Prior art keywords
making
methods
compositions
compounds
pharmaceuticals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0906579.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Priority to GBGB0906579.8A priority Critical patent/GB0906579D0/en
Publication of GB0906579D0 publication Critical patent/GB0906579D0/en
Priority to JP2011515594A priority patent/JP5559162B2/ja
Priority to CA2727444A priority patent/CA2727444C/en
Priority to AT09769578T priority patent/ATE544767T1/de
Priority to KR1020167026831A priority patent/KR20160116054A/ko
Priority to DK09769578.7T priority patent/DK2321321T3/da
Priority to PT09769578T priority patent/PT2321321E/pt
Priority to ES09769578T priority patent/ES2382154T3/es
Priority to EA201100079A priority patent/EA018803B1/ru
Priority to AU2009263976A priority patent/AU2009263976B2/en
Priority to NZ590590A priority patent/NZ590590A/en
Priority to EP09769578A priority patent/EP2321321B1/en
Priority to US12/997,721 priority patent/US8450328B2/en
Priority to KR1020117001954A priority patent/KR101680390B1/ko
Priority to PL09769578T priority patent/PL2321321T3/pl
Priority to MX2010013841A priority patent/MX2010013841A/es
Priority to PCT/GB2009/001605 priority patent/WO2009156737A1/en
Priority to BRPI0910182A priority patent/BRPI0910182B8/pt
Priority to KR1020187031734A priority patent/KR102008640B1/ko
Priority to CN200980124230.6A priority patent/CN102076692B/zh
Priority to IL210071A priority patent/IL210071A/en
Priority to ZA2011/00526A priority patent/ZA201100526B/en
Priority to US13/889,921 priority patent/US8987279B2/en
Priority to US14/618,829 priority patent/US9376443B2/en
Priority to IL243574A priority patent/IL243574B/en
Priority to US15/172,126 priority patent/US9765080B2/en
Priority to US15/682,346 priority patent/US10106547B2/en
Priority to US16/132,411 priority patent/US10538526B2/en
Priority to US16/700,160 priority patent/US10875868B2/en
Priority to US17/088,325 priority patent/US11466019B2/en
Priority to US17/895,037 priority patent/US20230100842A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
GBGB0906579.8A 2008-06-25 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same Ceased GB0906579D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GBGB0906579.8A GB0906579D0 (en) 2009-04-16 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same
BRPI0910182A BRPI0910182B8 (pt) 2008-06-25 2009-06-25 composto de fórmula (i), composição farmacêutica e uso de um composto
PL09769578T PL2321321T3 (pl) 2008-06-25 2009-06-25 Pochodne triazolo [4,5-d]pirymidyny i ich zastosowanie jako antagoniści receptora purynowego
MX2010013841A MX2010013841A (es) 2008-06-25 2009-06-25 Derivados de triazolo[4,5-d]pirimidina y su uso como antagonistas del receptor de purina.
AT09769578T ATE544767T1 (de) 2008-06-25 2009-06-25 Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten
KR1020167026831A KR20160116054A (ko) 2008-06-25 2009-06-25 트리아졸로〔4,5-ｄ〕피리미딘 유도체들 및 이들의 퓨린 수용체 안타고니스트로서의 용도
DK09769578.7T DK2321321T3 (da) 2008-06-25 2009-06-25 Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
PT09769578T PT2321321E (pt) 2008-06-25 2009-06-25 Derivados de triazolo[4,5-d]piramidina e seu uso como anatagonistas do receptor purina
ES09769578T ES2382154T3 (es) 2008-06-25 2009-06-25 Derivados de triazolo [4,5-D]piramidina y su uso como antagonistas de los receptores de purina
EA201100079A EA018803B1 (ru) 2008-06-25 2009-06-25 Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
AU2009263976A AU2009263976B2 (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d] pyramidine derivatives and their use as purine receptor antagonists
NZ590590A NZ590590A (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d] pyrimidine derivatives and their use as purine receptor antagonists
EP09769578A EP2321321B1 (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d]pyramidine derivatives and their use as purine receptor antagonists
US12/997,721 US8450328B2 (en) 2008-06-25 2009-06-25 Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists
KR1020117001954A KR101680390B1 (ko) 2008-06-25 2009-06-25 트리아졸로〔4,5-ｄ〕피리미딘 유도체들 및 이들의 퓨린 수용체 안타고니스트로서의 용도
JP2011515594A JP5559162B2 (ja) 2008-06-25 2009-06-25 プリン受容体アンタゴニストとしてのトリアゾロ［４，５−ｄ］ピリミジン誘導体およびその使用
PCT/GB2009/001605 WO2009156737A1 (en) 2008-06-25 2009-06-25 Triazolo [4, 5-d] pyramidine derivatives and their use as purine receptor antagonists
CN200980124230.6A CN102076692B (zh) 2008-06-25 2009-06-25 三唑并[4，5-d]嘧啶衍生物及其作为嘌呤受体拮抗剂的应用
CA2727444A CA2727444C (en) 2008-06-25 2009-06-25 Triazolo [4,5-d] pyramidine derivatives and their use as purine receptor antagonists
KR1020187031734A KR102008640B1 (ko) 2008-06-25 2009-06-25 트리아졸로〔4,5-ｄ〕피리미딘 유도체들 및 이들의 퓨린 수용체 안타고니스트로서의 용도
IL210071A IL210071A (en) 2008-06-25 2010-12-16 Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation
ZA2011/00526A ZA201100526B (en) 2008-06-25 2011-01-20 Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
US13/889,921 US8987279B2 (en) 2008-06-25 2013-05-08 Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antagonists
US14/618,829 US9376443B2 (en) 2008-06-25 2015-02-10 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
IL243574A IL243574B (en) 2008-06-25 2016-01-11 A pharmaceutical preparation for use in the treatment of a disease treatable by blocking purine receptors
US15/172,126 US9765080B2 (en) 2008-06-25 2016-06-02 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US15/682,346 US10106547B2 (en) 2008-06-25 2017-08-21 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US16/132,411 US10538526B2 (en) 2008-06-25 2018-09-15 Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
US16/700,160 US10875868B2 (en) 2008-06-25 2019-12-02 Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists
US17/088,325 US11466019B2 (en) 2008-06-25 2020-11-03 Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists
US17/895,037 US20230100842A1 (en) 2009-04-06 2022-08-24 Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0906579.8A GB0906579D0 (en) 2009-04-16 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
GB0906579D0 true GB0906579D0 (en) 2009-05-20

Family

ID=40750727

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0906579.8A Ceased GB0906579D0 (en) 2008-06-25 2009-04-16 Pharmaceuticals, compositions and methods of making and using the same

Country Status (20)

Country Link
US (9) US8450328B2 (cg-RX-API-DMAC7.html)
EP (1) EP2321321B1 (cg-RX-API-DMAC7.html)
JP (1) JP5559162B2 (cg-RX-API-DMAC7.html)
KR (3) KR102008640B1 (cg-RX-API-DMAC7.html)
CN (1) CN102076692B (cg-RX-API-DMAC7.html)
AT (1) ATE544767T1 (cg-RX-API-DMAC7.html)
AU (1) AU2009263976B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910182B8 (cg-RX-API-DMAC7.html)
CA (1) CA2727444C (cg-RX-API-DMAC7.html)
DK (1) DK2321321T3 (cg-RX-API-DMAC7.html)
EA (1) EA018803B1 (cg-RX-API-DMAC7.html)
ES (1) ES2382154T3 (cg-RX-API-DMAC7.html)
GB (1) GB0906579D0 (cg-RX-API-DMAC7.html)
IL (2) IL210071A (cg-RX-API-DMAC7.html)
MX (1) MX2010013841A (cg-RX-API-DMAC7.html)
NZ (1) NZ590590A (cg-RX-API-DMAC7.html)
PL (1) PL2321321T3 (cg-RX-API-DMAC7.html)
PT (1) PT2321321E (cg-RX-API-DMAC7.html)
WO (1) WO2009156737A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100526B (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
WO2010103547A2 (en) 2009-03-13 2010-09-16 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
BR112014028006A2 (pt) * 2012-05-30 2017-06-27 Hoffmann La Roche heterociclos de pirrolidino
US10781178B2 (en) 2015-08-12 2020-09-22 The General Hospital Corporation 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents
CA3009527C (en) * 2015-12-24 2024-01-09 Stephen WILLINGHAM Methods of treating cancer
US10793636B2 (en) 2016-07-11 2020-10-06 Corvus Pharmaceuticals, Inc. Anti-CD73 antibodies
KR20230156808A (ko) 2016-12-03 2023-11-14 주노 쎄러퓨티크스 인코퍼레이티드 Car-t 세포의 조절 방법
CA3045355A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
EP4310082A3 (en) 2017-01-20 2024-04-10 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
US10654825B2 (en) * 2017-03-30 2020-05-19 Corvus Pharmaceuticals, Inc. Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereof
US11040040B2 (en) 2017-04-04 2021-06-22 Corvus Pharmaceuticals, Inc. Methods of treating cancer
WO2018187508A1 (en) * 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
EP3607319A1 (en) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
EP3630132A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
US20220225597A1 (en) 2017-06-29 2022-07-21 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CA3080976A1 (en) * 2017-11-06 2019-05-09 Corvus Pharmaceuticals, Inc. Adenosine pathway inhibitors for cancer treatment
US20200277378A1 (en) 2017-11-16 2020-09-03 Novartis Ag Combination therapies
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
US20190231783A1 (en) 2018-02-01 2019-08-01 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
US11266649B2 (en) * 2018-02-01 2022-03-08 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
CA3089159A1 (en) 2018-02-06 2019-08-15 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
EP3765524A4 (en) 2018-03-14 2021-12-22 Surface Oncology, Inc. ANTIBODIES THAT BIND TO CD39 AND THEIR USES
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR102767594B1 (ko) 2018-07-12 2025-02-12 코버스 파마슈티칼스, 인크. 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법
CN112654365A (zh) 2018-07-12 2021-04-13 科尔沃斯制药股份有限公司 用于检测和治疗具有腺苷途径激活的癌症的方法
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
WO2020065036A1 (en) 2018-09-27 2020-04-02 Iteos Therapeutics S.A. Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist
WO2020068583A1 (en) * 2018-09-27 2020-04-02 Corvus Pharmaceuticals, Inc. Processes for making triazolo [4,5d] pyramidine derivatives and intermediates thereof
BE1026612B1 (fr) 2018-09-27 2020-07-02 Iteos Therapeutics S A Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
MA54079A (fr) 2018-11-01 2021-09-08 Juno Therapeutics Inc Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
EP3880238A1 (en) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
WO2020106558A1 (en) * 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
PL3886875T3 (pl) 2018-11-30 2024-09-09 Juno Therapeutics, Inc. Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
BR112021014833A2 (pt) 2019-01-29 2021-10-05 Juno Therapeutics, Inc. Anticorpos e receptores antigênicos quiméricos específicos para receptor órfão 1 de tipo tirosina quinase de receptor (ror1)
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
ES2982474T3 (es) 2019-02-15 2024-10-16 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202521984A (zh) 2019-09-25 2025-06-01 美商表面腫瘤學有限責任公司 抗ｉｌ－２７抗體及其用途
KR20210061202A (ko) * 2019-11-19 2021-05-27 일동제약(주) 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
CN114901640A (zh) * 2019-12-24 2022-08-12 兹杜斯生命科学有限公司 适用于治疗血脂异常的新型化合物
EP4110784A1 (en) 2020-02-26 2023-01-04 iTeos Belgium SA Pyrimido[5,4-d]pyrimidine derivatives as ent inhibitors for the treatment of cancers, and combination thereof with adenosine receptor antagonists
CA3179526A1 (en) 2020-04-07 2021-10-14 Michael Deligny Macrocyclic diamine derivatives as ent inhibitors for the treatment of cancers, and combination thereof with adenosine receptor antagonists
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
US20240141060A1 (en) 2021-01-29 2024-05-02 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
CN117136242A (zh) 2021-02-17 2023-11-28 Iteos比利时公司 化合物、组合物及其治疗方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CN119546638A (zh) 2022-06-22 2025-02-28 朱诺治疗学股份有限公司 用于cd19靶向的car t细胞的二线疗法的治疗方法
JP2025525937A (ja) 2022-08-05 2025-08-07 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
CN120712102A (zh) 2022-12-13 2025-09-26 朱诺治疗学股份有限公司 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
WO2024134541A1 (en) 2022-12-20 2024-06-27 iTeos Belgium SA Heterocyclic compounds as ent inhibitors and compounds for use in the treatment of cancers
WO2025104613A1 (en) 2023-11-14 2025-05-22 iTeos Belgium SA Ent1 inhibitors in combination with checkpoint inhibitors
KR20250123663A (ko) * 2024-02-08 2025-08-18 아이리드비엠에스 주식회사 Cxcr7 수용체 조절제 및 이의 용도

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56131586A (en) 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd Triazolopyrimidine derivative and its preparation
JPS56131587A (en) 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd 7-substituted triazolopyrimidine derivative and its preparation
JPS5962595A (ja) 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５，７―トリ置換―トリアゾロピリミジン誘導体
DE3304330A1 (de) 1983-02-09 1984-08-09 Basf Ag, 6700 Ludwigshafen Neue 2h-v-triazolyl(4,5-d)-pyrimidine und deren verwendung
JPS60140335A (ja) 1983-12-28 1985-07-25 Konishiroku Photo Ind Co Ltd 熱現像カラ−感光材料
US5204353A (en) 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
CZ101496A3 (en) 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
AU699034B2 (en) 1995-07-11 1998-11-19 Astrazeneca Ab New inhibitors of platelet aggregation
ZA971896B (en) 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
ES2273369T3 (es) 1996-08-28 2007-05-01 Pfizer Inc. Derivados 6,5 heterobiciclicos sustituidos.
CA2296014A1 (en) 1997-07-03 1999-01-14 Frank W. Hobbs Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
DE19736535C1 (de) 1997-08-22 1999-01-28 Basf Coatings Ag Basislackzusammensetzung sowie Verfahren zur Herstellung von mehrschichtigen Überzügen
US5939432A (en) 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
US6197788B1 (en) 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
EP1054012B1 (en) 1998-01-05 2003-06-11 Eisai Co., Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6326390B1 (en) 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
EP1221444B1 (en) 1999-07-02 2005-08-31 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
EP3719018B1 (en) * 2006-04-25 2025-08-27 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same

Also Published As

Publication number Publication date
CA2727444C (en) 2017-01-17
AU2009263976B2 (en) 2013-12-05
JP5559162B2 (ja) 2014-07-23
US10106547B2 (en) 2018-10-23
KR20110057122A (ko) 2011-05-31
ATE544767T1 (de) 2012-02-15
CN102076692A (zh) 2011-05-25
US20110172252A1 (en) 2011-07-14
US8450328B2 (en) 2013-05-28
US20150291602A1 (en) 2015-10-15
JP2011525898A (ja) 2011-09-29
US11466019B2 (en) 2022-10-11
IL210071A0 (en) 2011-02-28
US20210115054A1 (en) 2021-04-22
AU2009263976A1 (en) 2009-12-30
PT2321321E (pt) 2012-05-15
DK2321321T3 (da) 2012-05-21
WO2009156737A1 (en) 2009-12-30
MX2010013841A (es) 2011-02-25
US20200172547A1 (en) 2020-06-04
US9765080B2 (en) 2017-09-19
ZA201100526B (en) 2012-04-25
EP2321321A1 (en) 2011-05-18
ES2382154T3 (es) 2012-06-05
US20130245044A1 (en) 2013-09-19
US10875868B2 (en) 2020-12-29
CA2727444A1 (en) 2009-12-30
KR101680390B1 (ko) 2016-11-28
US20170088552A1 (en) 2017-03-30
PL2321321T3 (pl) 2012-07-31
US10538526B2 (en) 2020-01-21
BRPI0910182A2 (pt) 2017-05-30
US20230100842A1 (en) 2023-03-30
US20170342081A1 (en) 2017-11-30
US9376443B2 (en) 2016-06-28
BRPI0910182B1 (pt) 2020-10-27
IL210071A (en) 2016-02-29
KR20160116054A (ko) 2016-10-06
EA018803B1 (ru) 2013-10-30
KR20180122482A (ko) 2018-11-12
IL243574B (en) 2019-03-31
CN102076692B (zh) 2014-10-22
US20190031668A1 (en) 2019-01-31
KR102008640B1 (ko) 2019-08-07
EA201100079A1 (ru) 2011-08-30
BRPI0910182B8 (pt) 2021-05-25
NZ590590A (en) 2011-12-22
EP2321321B1 (en) 2012-02-08
US8987279B2 (en) 2015-03-24

Similar Documents

Publication Publication Date Title
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN02735A (cg-RX-API-DMAC7.html)
IN2012DN00754A (cg-RX-API-DMAC7.html)
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
CA2871471C (en) Dna-pk inhibitors
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
AU2011234398A8 (en) Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
WO2011121418A9 (en) 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
MX366318B (es) Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
UA96037C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиалкогольного действия
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)